Clinical trial
A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants With Advanced Melanoma (KEYNOTE-555)
NCT03665597 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants With Advanced Melanoma (KEYNOTE-555)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 19, 2018
- Completion date
- December 4, 2023
- Enrollment
- 138 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.